Healthcare | Equity Research | February 19, 2026
Target: $197.8
$155.0
8.4x
$18.47
1.44%
Conviction: High
The company exhibits solid fundamentals with stable cash flow generation. Operational efficiency programs are yielding margin improvements. Johnson & Johnson is positioned to benefit from secular tailwinds in the Healthcare industry.
Risks: Macroeconomic volatility and interest rate sensitivity remain key risks. Competitive pressures in the sector could impact market share.
| Year | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (E) | 2026 (E) | 2027 (E) |
|---|---|---|---|---|---|---|
| Revenue | $177.3 | $184.8 | $189.5 | $194.3 | $201.3 | $204.7 |
| Consensus Rev | - | - | - | $197.1 | $211.3 | $208.3 |
| System Rev | - | - | - | $199.9 | $199.5 | $205.8 |
| EBITDA | $67.1 | $67.6 | $82.0 | $42.1 | $79.9 | $54.8 |
| EPS | $15.12 | $15.23 | $18.47 | $9.48 | $18.0 | $12.36 |
Breakdown: 39 Buy / 3 Hold / 2 Sell
The street remains generally buyish on the name.